CDMO Lonza will integrate Simris’s antibody-drug conjugate (ADC) payload technology into its bioconjugation services. Swedish biotech Simris Biolgics, previously known as Cyano Biotech, has entered a strategic partnership to make contract development and manufacturing organization (CDMO) Lonza its preferred partner for the commercialization of its ADC payload platform. Under terms of the deal, financials of which have not been divulged, Lonza will gain the exclusive right to offer the technology to customers seeking payloads to develop into ADCs, while Simris…